Final overall survival (OS) for abemaciclib plus trastuzumab plus /- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

被引：16
|
作者：
Andre, F. [1 ]
Nadal, J. C. [2 ]
Denys, H. [3 ]
Goel, S. [4 ]
Litchfield, L. M. [5 ]
Appiah, A. [5 ]
Chen, Y. [5 ]
Tolaney, S. M. [6 ]
机构：
[1] Gustave Roussy Canc Campus, Dept Med Oncol, Breast Canc Unit, Villejuif, France
[2] Inst Alexander Fleming, Dept Clin Oncol, Buenos Aires, DF, Argentina
[3] Univ Ziekenhuis Gent, Dept Med Oncol, Ghent, Belgium
[4] Peter MacCallum Canc Ctr, Dept Canc Res, Melbourne, Vic, Australia
[5] Eli Lilly & Co Global Headquarters, Oncol, Indianapolis, IN USA
[6] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.08.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA18
引用
收藏
页码：S1386 / S1387
页数：2
相关论文
共 50 条
  • [41] A randomized trial of abemaciclib in combination with fulvestrant compared to chemotherapy in women with HR+, HER2-advanced breast cancer with visceral metastases
    Kaufman, Peter
    Glaspy, John
    Zhang, Wei
    Koustenis, Andrew
    Chen, Yanyun
    Brufsky, Adam
    CANCER RESEARCH, 2020, 80 (04)
  • [42] Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial
    Jerusalem, G.
    Delea, T.
    Martin Jimenez, M.
    De laurentiis, M.
    Nusch, A.
    Beck, J. T.
    Chan, A.
    Im, S-A.
    Neven, P.
    Lonshteyn, A.
    Chandiwana, D.
    Lanoue, B.
    Fasching, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S66 - S66
  • [43] HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer
    Miller, Kathy
    Cortes, Javier
    Hurvitz, Sara A.
    Krop, Ian E.
    Tripathy, Debu
    Verma, Sunil
    Riahi, Kaveh
    Reynolds, Joseph G.
    Wickham, Thomas J.
    Molnar, Istvan
    Yardley, Denise A.
    BMC CANCER, 2016, 16
  • [44] A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP
    Takano, Toshimi
    Tsurutani, Junji
    Takahashi, Masato
    Yamanaka, Takeharu
    Sakai, Kazuko
    Ito, Yoshinori
    Fukuoka, Junya
    Kimura, Hideharu
    Kawabata, Hidetaka
    Tamura, Kenji
    Matsumoto, Koji
    Aogi, Kenjiro
    Sato, Kazuhiko
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    Saeki, Toshiaki
    BREAST, 2018, 40 : 67 - 75
  • [45] Abemaciclib for Patients with advanced or metastatic HR plus Breast Cancer and HER2-Breast Cancer Benefits in Overall Survival - even in Patients with visceral Metastases
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (06)
  • [46] NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel plus trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
    Jacobs, Samuel A.
    Robidoux, Andre
    Abraham, Jame
    Manuel Perez-Garcia, Jose
    La Verde, Nicla
    Orcutt, James M.
    Cazzaniga, Marina E.
    Piette, Fanny
    Antolin, Silvia
    Aguirre, Elena
    Cortes, Javier
    Llombart-Cussac, Antonio
    Di Cosimo, Serena
    Kim, Rim S.
    Feng, Huichen
    Lipchik, Corey
    Lucas, Peter C.
    Srinivasan, Ashok
    Wang, Ying
    Song, Nan
    Gavin, Patrick G.
    Balousek, April D.
    Paik, Soonmyung
    Allegra, Carmen J.
    Wolmark, Norman
    Pogue-Geile, Katherine L.
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [47] Chemotherapy plus HER2-targeted therapy versus endocrine therapy plus HER2-targeted therapy as first-line treatment in patients with HR+/HER2+advanced breast cancer: A real-world trial
    Liang, Yuehua
    Li, Hui Ping
    Yun, Zehui
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [48] A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab
    Xu, Binghe
    Ma, Fei
    Ouyang, Quchang
    Li, Wei
    Jiang, Zefei
    Tong, Zhongsheng
    Liu, Yunjiang
    Li, Huiping
    Yu, Shiying
    Feng, Jifeng
    Wang, Shusen
    Hu, Xichun
    Zhu, Xiaoyu
    Zou, Jianjun
    CANCER RESEARCH, 2018, 78 (04)
  • [49] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    ONCOLOGIST, 2013, 18 (06): : 661 - 666
  • [50] Everolimus plus trastuzumab and vinorelbine for trastuzumabresistant, taxane-pretreated, HER2+advanced breast cancer: Overall survival results from BOLERO-3
    Isaacs, C.
    O'Regan, R.
    Xu, B.
    Masuda, N.
    Arena, F.
    Yap, Y-S
    Papal, Z.
    Lang, I.
    Armstrong, A.
    Lerzo, G.
    White, M.
    Shen, K.
    Zhang, Y.
    Jappe, A.
    Pacaud, L. B.
    Taran, T.
    Ozguroglu, M.
    CANCER RESEARCH, 2016, 76
12345